Which has stronger earnings & valuation, PODD or AXGN?

Insulet has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.72 $247.10M $5.35 27.13 AxoGen $225.21M 12.29 -$15.70M -$0.68 N/A

Is PODD or AXGN more profitable?

Insulet has a net margin of 12.29% compared to AxoGen's net margin of -13.36%. Insulet's return on equity of 29.29% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% AxoGen -13.36% -8.90% -6.47%

Does the media favor PODD or AXGN?

In the previous week, Insulet had 44 more articles in the media than AxoGen. MarketBeat recorded 53 mentions for Insulet and 9 mentions for AxoGen. AxoGen's average media sentiment score of 1.48 beat Insulet's score of 0.65 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 21 Very Positive mention(s) 2 Positive mention(s) 29 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, AXGN or TFX?

AxoGen has higher earnings, but lower revenue than Teleflex. AxoGen is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 12.29 -$15.70M -$0.68 N/A Teleflex $1.99B 2.97 -$905.64M -$23.29 N/A

Is AXGN or TFX more profitable?

AxoGen has a net margin of -13.36% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Teleflex -39.67% 11.93% 5.44%

Does the media prefer AXGN or TFX?

In the previous week, Teleflex had 4 more articles in the media than AxoGen. MarketBeat recorded 13 mentions for Teleflex and 9 mentions for AxoGen. AxoGen's average media sentiment score of 1.48 beat Teleflex's score of 0.85 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teleflex 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXGN or MMED?

In the previous week, AxoGen and AxoGen both had 9 articles in the media. AxoGen's average media sentiment score of 1.48 beat MiniMed Group's score of 1.00 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, AXGN or HAE?

Haemonetics has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 12.29 -$15.70M -$0.68 N/A Haemonetics $1.33B 3.54 $97.31M $2.04 50.90

Is AXGN or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to AxoGen's net margin of -13.36%. Haemonetics' return on equity of 27.55% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Haemonetics 7.12% 27.55% 9.65%

Does the media prefer AXGN or HAE?

In the previous week, Haemonetics had 12 more articles in the media than AxoGen. MarketBeat recorded 21 mentions for Haemonetics and 9 mentions for AxoGen. AxoGen's average media sentiment score of 1.48 beat Haemonetics' score of 0.61 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LIVN or AXGN?

AxoGen has lower revenue, but higher earnings than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.19 -$242.47M $3.38 23.76 AxoGen $225.21M 12.29 -$15.70M -$0.68 N/A

Is LIVN or AXGN more profitable?

LivaNova has a net margin of 12.82% compared to AxoGen's net margin of -13.36%. LivaNova's return on equity of 16.35% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% AxoGen -13.36% -8.90% -6.47%

Does the media favor LIVN or AXGN?

In the previous week, AxoGen had 7 more articles in the media than LivaNova. MarketBeat recorded 9 mentions for AxoGen and 2 mentions for LivaNova. AxoGen's average media sentiment score of 1.48 beat LivaNova's score of 0.04 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AxoGen (AXGN) Competitors

$51.47 -0.26 (-0.50%)

As of 04:00 PM Eastern

Compare

AXGN vs. PODD, TFX, MMED, HAE, and LIVN

Should you buy AxoGen stock or one of its competitors? AxoGen's main competitors and comparable companies include Insulet (PODD), Teleflex (TFX), MiniMed Group (MMED), Haemonetics (HAE), and LivaNova (LIVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does AxoGen compare to Insulet?

Insulet (NASDAQ:PODD) and AxoGen (NASDAQ:AXGN) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Insulet has a net margin of 12.29% compared to AxoGen's net margin of -13.36%. Insulet's return on equity of 29.29% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
AxoGen	-13.36%	-8.90%	-6.47%

80.3% of AxoGen shares are held by institutional investors. 0.4% of Insulet shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Insulet has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

In the previous week, Insulet had 44 more articles in the media than AxoGen. MarketBeat recorded 53 mentions for Insulet and 9 mentions for AxoGen. AxoGen's average media sentiment score of 1.48 beat Insulet's score of 0.65 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	21 Very Positive mention(s)	2 Positive mention(s)	29 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet presently has a consensus target price of $195.40, suggesting a potential upside of 34.64%. AxoGen has a consensus target price of $51.56, suggesting a potential upside of 0.17%. Given Insulet's higher possible upside, equities analysts clearly believe Insulet is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Insulet has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.72	$247.10M	$5.35	27.13
AxoGen	$225.21M	12.29	-$15.70M	-$0.68	N/A

Summary

Insulet beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does AxoGen compare to Teleflex?

AxoGen (NASDAQ:AXGN) and Teleflex (NYSE:TFX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

AxoGen has higher earnings, but lower revenue than Teleflex. AxoGen is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	12.29	-$15.70M	-$0.68	N/A
Teleflex	$1.99B	2.97	-$905.64M	-$23.29	N/A

AxoGen has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

AxoGen currently has a consensus target price of $51.56, indicating a potential upside of 0.17%. Teleflex has a consensus target price of $152.90, indicating a potential upside of 9.36%. Given Teleflex's higher probable upside, analysts plainly believe Teleflex is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

AxoGen has a net margin of -13.36% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Teleflex	-39.67%	11.93%	5.44%

In the previous week, Teleflex had 4 more articles in the media than AxoGen. MarketBeat recorded 13 mentions for Teleflex and 9 mentions for AxoGen. AxoGen's average media sentiment score of 1.48 beat Teleflex's score of 0.85 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teleflex	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 0.7% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

AxoGen beats Teleflex on 9 of the 17 factors compared between the two stocks.

How does AxoGen compare to MiniMed Group?

AxoGen (NASDAQ:AXGN) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiniMed Group has a net margin of 0.00% compared to AxoGen's net margin of -13.36%. MiniMed Group's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
MiniMed Group	N/A	N/A	N/A

AxoGen currently has a consensus price target of $51.56, indicating a potential upside of 0.17%. MiniMed Group has a consensus price target of $21.62, indicating a potential upside of 7.54%. Given MiniMed Group's higher probable upside, analysts clearly believe MiniMed Group is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

AxoGen has higher earnings, but lower revenue than MiniMed Group. AxoGen is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	12.29	-$15.70M	-$0.68	N/A
MiniMed Group	$3.10B	1.82	-$333M	-$0.68	N/A

In the previous week, AxoGen and AxoGen both had 9 articles in the media. AxoGen's average media sentiment score of 1.48 beat MiniMed Group's score of 1.00 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiniMed Group beats AxoGen on 7 of the 12 factors compared between the two stocks.

How does AxoGen compare to Haemonetics?

AxoGen (NASDAQ:AXGN) and Haemonetics (NYSE:HAE) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Haemonetics has a net margin of 7.12% compared to AxoGen's net margin of -13.36%. Haemonetics' return on equity of 27.55% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Haemonetics	7.12%	27.55%	9.65%

AxoGen presently has a consensus price target of $51.56, indicating a potential upside of 0.17%. Haemonetics has a consensus price target of $97.56, indicating a potential downside of 6.04%. Given AxoGen's stronger consensus rating and higher possible upside, research analysts clearly believe AxoGen is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 2.1% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Haemonetics has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	12.29	-$15.70M	-$0.68	N/A
Haemonetics	$1.33B	3.54	$97.31M	$2.04	50.90

In the previous week, Haemonetics had 12 more articles in the media than AxoGen. MarketBeat recorded 21 mentions for Haemonetics and 9 mentions for AxoGen. AxoGen's average media sentiment score of 1.48 beat Haemonetics' score of 0.61 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Summary

Haemonetics beats AxoGen on 10 of the 17 factors compared between the two stocks.

How does AxoGen compare to LivaNova?

LivaNova (NASDAQ:LIVN) and AxoGen (NASDAQ:AXGN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

LivaNova currently has a consensus target price of $83.50, suggesting a potential upside of 3.96%. AxoGen has a consensus target price of $51.56, suggesting a potential upside of 0.17%. Given LivaNova's higher probable upside, equities analysts plainly believe LivaNova is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

AxoGen has lower revenue, but higher earnings than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.19	-$242.47M	$3.38	23.76
AxoGen	$225.21M	12.29	-$15.70M	-$0.68	N/A

97.6% of LivaNova shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LivaNova has a net margin of 12.82% compared to AxoGen's net margin of -13.36%. LivaNova's return on equity of 16.35% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
AxoGen	-13.36%	-8.90%	-6.47%

In the previous week, AxoGen had 7 more articles in the media than LivaNova. MarketBeat recorded 9 mentions for AxoGen and 2 mentions for LivaNova. AxoGen's average media sentiment score of 1.48 beat LivaNova's score of 0.04 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LivaNova and AxoGen tied by winning 8 of the 16 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXGN vs. The Competition

Export

Metric	AxoGen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.78B	$5.80B	$7.24B	$12.93B
Dividend Yield	N/A	1.76%	2.54%	10.96%
P/E Ratio	-75.69	25.67	271.21	25.38
Price / Sales	12.29	68.39	623.95	92.16
Price / Cash	N/A	32.99	79.29	54.21
Price / Book	10.79	6.18	12.95	6.14
Net Income	-$15.70M	$148.22M	$3.46B	$347.93M
7 Day Performance	2.12%	-0.34%	-0.16%	-0.77%
1 Month Performance	25.08%	7.34%	7.32%	3.80%
1 Year Performance	217.32%	5.80%	23.87%	14.69%

AxoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXGN AxoGen	2.0503 of 5 stars	$51.47 -0.5%	$51.56 +0.2%	+220.5%	$2.78B	$225.21M	N/A	450	Positive News Analyst Forecast
PODD Insulet	4.7086 of 5 stars	$143.13 -1.6%	$195.40 +36.5%	-57.1%	$9.92B	$2.71B	26.73	5,400	Trending News
TFX Teleflex	3.4823 of 5 stars	$136.39 -1.4%	$152.90 +12.1%	+6.4%	$5.78B	$1.99B	N/A	15,500	Positive News Analyst Forecast Short Interest Increase
MMED MiniMed Group	2.1364 of 5 stars	$19.57 -1.9%	$21.62 +10.5%	N/A	$5.46B	$3.10B	N/A	2,800	News Coverage Lockup Expiration
HAE Haemonetics	2.6457 of 5 stars	$107.73 -0.6%	$97.56 -9.4%	+90.6%	$4.90B	$1.35B	52.81	3,009	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXGN) was last updated on 8/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Competitors